A Specialty Bio-pharmaCeutical Company, with unique drug delivery technology. Fighting blindness together.
Harnessing the possibilities in new biologic and nucleic acid therapies, BioHealthWays precisely controls safety, targeting, timing, and dosing by exploiting practical advances in drug delivery technology. Doing so, BioHealthWays discovers and differentiates therapies that elevate the human condition and improve the comfort of living.
Customized Drug Delivery, enabled by polymeric nanotechnology, is a key to drugs with improved safety, efficacy, toxicology, and release profiles.
Our expertise is in biomaterials and nanotechnologies, particularly block copolymers, hydrogels, and material properties. We are creating assets with optimized product attributes to exceed customer, regulatory, and market requirements.
In Focus: Nanotechnology-based drug delivery systems for ocular biologic therapeutics
The following eye diseases are common examples of often chronic and require thoughtful treatments with enhanced drug delivery profiles to treat 100M+ global patients:
- retinal neo-vascular conditions (diabetic and age-related)
- secondary glaucoma
These "top 3" diseases are increasingly treated with biologics. Currently, they require multiple injections and are particularly challenging to deliver inside the eye, a complicated, sensitive organ.
- Premise: Ocular biologic therapeutics require specialized drug delivery mechanisms to provide effective dosing for longer than ever, in safe, convenient-to-use, and convenient-to-administer forms.
- Insight: BioHealthWays has a implantable drug delivery system designed to achieve sustained release of biologics for >6 months intraocularly.
- Result: Working with partners, BioHealthWays optimizes preclinical pipeline assets to generate competitive product attributes.
We will work with you to create best-in-class therapeutic attributes. Contact us today.
Chief Executive Officer
Brian is the cofounder and CEO of BioHealthWays. Prior to BioHealthWays, Brian was a strategic advisor at Galt & Company, a firm that delivers high value strategies and implements operating conditions, to exceed customer and shareholder expectations. He has supported notable divestitures, acquisitions, and resource allocation strategies across corporate functional areas. Before Galt & Company, Brian worked at Accenture Strategy. Fortune 500 clients include: Coca-Cola, Caterpillar, Abbott Medical Optics, Bristol Myers Squibb, Fiat-Chrysler Automobiles, AT&T, Pitney Bowes.
Johannesburg, South Africa (12 months), Dubai, UAE (4 months), Jeddah, Saudi Arabia (4 months), Geneva, Switzerland (4 months), Istanbul, Turkey (12 months), Various intermittent locations Domestic and Global
Board, Columbia Engineering Young Alumni
B.S. IEOR: Engineering and Management Systems, Economics, Technical Entrepreneurship, Columbia University Fu Foundation School of Engineering and Applied Science with selected studies at Columbia Business School (MBA)
Dr. David Pan
President and Chief Technology Officer
David is co-founder, President, and Chief Technology/Business Officer of BioHealthWays, Inc. David brings a unique combination of corporate commercialization and innovation as well as patent expertise. Having served at Xerox Corporation for over 32 years in various senior roles at the Office of General Counsel as well as Offices of Corporate Innovation and Research & Development, David has nearly 100 patents to his name, several of which have been commercialized and/or out-licensed. Products utilizing his technology include: e-ink as used in the Kindle reader, various technologies in Xerox printers, and biomaterials in biomedical imaging. Through his innovations, he has delivered over $100M+ in customer value. David is an expert in product delivery of hydrogels, polymers, block copolymers, elastomer nano-composites, polymer chemistry, physics, engineering, and structure-property relationships. He has unusual expertise as an inventor and patents infringement investigator, and is called as an expert witness for general IP defense expertise in U.S. court investigations.
David is a member of various professional societies, including American Chemical Society, American Physical Society, and Materials Research Society. He has received numerous corporate awards and session chairmanships. He has written over 25 journal-accepted publications, and given multiple public talks at research organizations, professional societies, and conferences worldwide.
- Hydrogels, Polymers, Block Copolymers, polymer chemistry
- Elastomer nano-composites
- Physics, Engineering, Structure-property relationships
Ph.D. Chemical Engineering, University of Wisconsin-Madison
B.Eng. Chemical Engineering, National Taiwan University
Increasing revenue share of biopharma
Why Biologics Drug Delivery?
Biologics and nucleic-acid based therapies are not only growing in importance in the R&D pipeline, but also capturing an increasing and profitable share of pharmaceutical market revenues. In the coming few years, as value-based pricing is implemented, superior products will maintain competitive pricing advantages.
BioHealthWays technology will align within the 1000's of biologics now in large pharma's R&D pipeline. This represents well over $25 billion dollars of annual investments. To protect and enhance assets in your R&D pipeline, ensure your products have an enhanced drug delivery mechanism from BioHealthWays.
Follow the links below to learn more about Growth in Biopharma and Medicare Provider Utilization data to see the growth in the industry and the increasing importance of sustainable health technologies.
Nanotechnology example: nanomicelles
BioHealthWays' product is rooted in nanotechnology. The clinical application of nanotechnology--such as block copolymer micelles--is rapidly developing. New approaches and opportunities using these and other technologies will create new product applications--spanning biologic and nucleic-acid therapies. Repurposing, biosimilars, cocktail drugs, and related strategic initiatives in the "drug delivery" toolbox are vastly underutilized and could unlock additional value while being efficient with R&D spend.
"The use of nanotechnology is expected to provide pharmaceuticals with improved dissolution, bioavailability, metabolism, clearance, and distribution profiles, which are hoped to reduce unwanted side effects and improve efficacy." US Dep of Health and Human Services, Food and Drug Administration, 2014 - Guidance for Industry: Considering whether an FDA-regulated product involves the application of nanotechnology.
Follow the links below to read more about a few current approaches and opportunities in the field.
Enhanced Drug Delivery Technology
BioHealthWays has investment opportunities for accredited US and foreign investors. Learn more about the progress we are making today, and how you can support a truly worthwhile, meaningful, and valuable cause.
We like hearing from you!